



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: David E. Francischelli, et al.

Examiner: Scott M. Getzow

Serial No.: 10/684,628

Group Art Unit: 3762

Filing Date: 10-14-2003

Docket No.: P-10033.02

Title: METHOD AND SYSTEM FOR TREATMENT OF ATRIAL TACHYARRHYTHMIAS

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8: I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 30th day June, 2006.


Signature

Jeffrey J. Hohenstetl
Printed Name

TERMINAL DISCLAIMER UNDER 37 C.F.R. § 1.321(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate Under 37 C.F.R. § 3.73(b)

Your petitioner, Medtronic, Inc., a corporation of the State of Minnesota having a place of business at 710 Medtronic Parkway, Minneapolis, Minnesota, certifies that it is the exclusive owner of the entire right, title and interest in and to the above-identified patent application (Serial No. 10/684,628) and in and to U.S. Patent application Serial No. 10/016,299. U.S. Patent Application Serial No. 10/016,299 is now U.S. Patent No. 6,656,175.

Your petitioner owns the entire right, title and interest in and to the above-identified patent application Serial No. 10/684,628. The assignment for U.S. Patent Application Serial No. 10/016,299 was recorded on December 11, 2001 at Reel 012399/Frame 0698 (PG4), with the United States Patent and Trademark Office. U.S. Patent Application Serial No 10/684,628 is a continuation application of U.S. Patent Application Serial No. 10/016,299.

The undersigned (whose title is supplied below) is empowered to act on behalf of Petitioner.

Documents establishing the chain of title of the subject patent application (including the aforementioned assignment and a notice from the Patent and Trademark Office noting its recording location) have been reviewed and I certify that, to the best of my knowledge and belief, title is in Petitioner.

Terminal Disclaimer

Petitioner hereby disclaims, except as provided below, the terminal part of any patent granted on the above-identified patent application that would extend beyond the expiration date of a full statutory term as defined in 35 U.S.C. §154 to §156 and §173 of U.S. Patent No. 6,656,175, not shortened by terminal disclaimer. Petitioner hereby agrees that any patent granted on the above-identified patent application shall be enforceable only for and during such period that the legal title to such patent and U.S. Patent No. 6,656,175 are commonly owned. This agreement is to run with any patent granted on the above-identified patent application and to be binding upon the grantee, its successors and assigns.

Limitations on the Disclaimer

In making the above disclaimer, Petitioner does not disclaim any terminal part of any patent granted on the above-identified patent application prior to the expiration date of the full statutory term, not shortened by terminal disclaimer, of U.S. Patent No. 6,656,175, if such patent: (1) expires for failure to pay a maintenance fee; (2) is held unenforceable or is found invalid by a court of competent jurisdiction; (3) is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321; (4) has all claims canceled by a reexamination certificate; (5) is reissued; or (6) is otherwise terminated prior to the expiration of its full statutory term.

TERMINAL DISCLAIMER

Page 3

Serial No. 10/684,628

Dkt.: P-10033.02

Filing Date: November 14, 2003


Title: METHOD AND SYSTEM FOR TREATMENT OF ATRIAL TACHYARRHYTHMIAS

I hereby declare that all statements made herein of my own knowledge are true and that all statements made herein on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the above-identified application or any patent issuing thereon.

Please charge \$130.00 to Deposit Account No. 13-2546 for the fee required by 37 C.F.R. § 1.20(d). Please charge any additional required fees or credit any overpayment to Deposit Account No. 13-2546.

Date: 6/30, 2006

Respectfully submitted,



Earle F. Kyle, IV
Vice President, Senior Counsel
Medtronic, Inc.
7611 Northland Drive
Minneapolis, MN 55428
Telephone: (763) 391-9280
Fax. (763) 391-9668